The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, open-label study of the efficacy and safety of galinpepimut-S (GPS) maintenance monotherapy compared to investigator's choice of best available therapy (BAT) in patients with acute myeloid leukemia (AML) who have achieved complete remission (CR) after second-line salvage therapy.
 
Omer Hassan Jamy
No Relationships to Disclose
 
Sharif S. Khan
No Relationships to Disclose
 
Panagiotis Tsirigotis
No Relationships to Disclose
 
Benjamin Kent Tomlinson
No Relationships to Disclose
 
Mathilde Hunault-Berger
No Relationships to Disclose
 
Uwe Platzbecker
Honoraria - Abbvie; Celgene/Jazz; Curis; Geron; Janssen
Consulting or Advisory Role - BMS GmbH & Co. KG; Celgene/Jazz; Novartis
Research Funding - Amgen (Inst); BerGenBio (Inst); Celgene (Inst); Curis (Inst); Janssen (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - part of a patent for a TFR-2 antibody (Rauner et al. Nature Metabolics 2019)
Travel, Accommodations, Expenses - Celgene
 
Ioanna Sakellari
No Relationships to Disclose
 
Ana Vidovic
No Relationships to Disclose
 
Pau Montesinos
No Relationships to Disclose
 
Teresa Bernal del Castillo
No Relationships to Disclose
 
Daniel Egan
No Relationships to Disclose
 
Hana Safah
No Relationships to Disclose
 
Gary J. Schiller
Stock and Other Ownership Interests - Amgen; Bristol-Myers Squibb; Johnson & Johnson
Consulting or Advisory Role - Abbvie; Agios; Astellas Pharma; Celgene; Incyte; Jazz Pharmaceuticals; Novartis; Ono Pharmaceutical
Speakers' Bureau - Abbvie; Astellas Pharma; Bristol-Myers Squibb; Incyte; Jazz Pharmaceuticals; Karyopharm Therapeutics; Kite, a Gilead company; Sanofi; Stemline Therapeutics
Research Funding - Abbvie; Actinium Pharmaceuticals; Actuate Therapeutics; Agios; Amgen; Arog; Astellas Pharma; AVM Biotechnology; Bristol-Myers Squibb/Celgene; Celator; Constellation Pharmaceuticals; Daiichi Sankyo; Deciphera; Delta-Fly Pharma; ElevateBio; FORMA Therapeutics; Fujifilm; Gamida Cell; Genentech/Roche; Geron; Incyte; Jazz Pharmaceuticals; Karyopharm Therapeutics; Kite, a Gilead company; Mateon Therapeutics; Novartis; Onconova Therapeutics; Ono Pharmaceutical; Pfizer; PrECOG; REGiMMUNE; Samus Therapeutics; Sangamo Bioscience; Sanofi; Sellas Life Sciences; Stemline Therapeutics; Syros Pharmaceuticals; Takeda; Tolero Pharmaceuticals; Trovagene
 
Mathias Haenel
No Relationships to Disclose
 
Agata Obara
No Relationships to Disclose
 
Tsung-Chih Chen
No Relationships to Disclose
 
Marcello Rotta
No Relationships to Disclose
 
Stavroula Giannouli
No Relationships to Disclose
 
Aleksandar Savic
Consulting or Advisory Role - Amicus Therapeutics; Pfizer
Speakers' Bureau - Abbvie; AstraZeneca; Roche; Sandoz; Takeda
Travel, Accommodations, Expenses - Amicus Therapeutics
 
Dragan Cicic
No Relationships to Disclose